Tumor treating fields (TTFields) for patients with glioblastoma
In Switzerland, tumour treating fields (TTFields) for the treatment of newly diagnosed glioblastoma are reimbursed through the statutory health insurance under certain circumstances. To evaluate the reimbursement obligation, a HTA was commissioned with the aim of investigating the efficacy, safety, cost-effectiveness and budgetary impact of TTFields for patients with glioblastoma. As well as the use of TTFields for newly diagnosed glioblastoma, the HTA also examines their use in recurring glioblastoma. The ethical, legal, organisational and social aspects of treatment with TTFields are also evaluated in the HTA report.